97 results about "IMMUNE FLUORESCENCE" patented technology

The invention belongs to biotechnology, and particularly relates to an African swine fever virus p30 protein monoclonal antibody as well as a preparation method and application thereof. The main technology comprises the following steps: immunizing a BALB / c mouse by using a recombinant p30 protein prepared by prokaryotic expression as an antigen, and carrying out cell fusion, indirect ELISA method screening, limited dilution method subcloning and hybridoma continuous subculture by using a hybridoma technology to obtain a hybridoma cell line capable of stably secreting an anti-African swine fever virus p30 protein monoclonal antibody. The invention also discloses a sequence of an immunogen of the prepared monoclonal antibody, a subtype of the monoclonal antibody, a CDR sequence, a preservation number of a hybridoma cell strain and application of the monoclonal antibody in a Western Blot experiment, an indirect immunofluorescence experiment, a neutralization experiment and a blocking ELISA method for detecting the African swine fever virus antibody in swine serum.

The invention discloses an anti-human inflammatory factor interleukin 6 monoclonal antibody and an application thereof. When the monoclonal antibody is prepared, an adopted immunogen is a human inflammatory factor interleukin 6 antigen, and an amino acid sequence of the human inflammatory factor interleukin 6 antigen comprises a sequence as shown in SEQ ID NO: 1. A group of monoclonal antibodies specifically combined with antigens is constructed based on the IL-6 antigens. The IL-6 monoclonal antibody has strong binding capacity with an IL-6 antigen in a clinical sample, has no cross reaction with other proteins, has good specificity and affinity compared with a commercial antigen, can be effectively applied to ELISA and a dry-type immunofluorescence method, has good detection linearity, precision, stability and accuracy, and can be widely applied to the field of immunoassay. The antibody can be combined with the antigen to serve as a detection reagent raw material combination, and has clinical detection advantages.

The invention relates to the technical field of biology, in particular to an anti-B7-H3 monoclonal antibody, a hybridoma cell strain and application thereof. The invention provides a monoclonal antibody. Amino acid sequences of three CDR regions of a heavy chain of the monoclonal antibody respectively have amino acid sequences shown as SEQ ID NO: 11, 12 and 13; the amino acid sequences of the three CDR regions of the light chain of the gene respectively have the amino acid sequences shown as SEQ ID NO: 6, 7 and 8. The anti-B7-H3 monoclonal antibody provided by the invention can be used for specifically recognizing a B7-H3 recombinant protein expressed by eukaryotic expression and a B7-H3 protein expressed on a cell membrane. A B7-H3 detection kit constructed by the anti-B7-H3 monoclonal antibody is high in sensitivity and good in specificity, and has a better application effect in various detections including enzyme-linked immunosorbent assay, flow cytometry, immunofluorescence and the like.

The invention discloses application of a host factor MOV10 in development of rabies treatment medicines and vaccine production, and belongs to the technical field of biological medicines. In order to research the influence of the host factor MOV10 on the replication of the RABV, the invention discovers that the overexpression host factor MOV10 coding gene can inhibit the replication of the RABV through the technologies of real-time fluorescent quantitative PCR (Polymerase Chain Reaction), Western Blotting, direct immunofluorescence and the like; then, a mov10 gene knockout cell line is successfully constructed through a CRISPR / Cas9 gene editing technology, the cell proliferation activity of the mov10 gene knockout cell line and the influence of the mov10 gene knockout cell line on RABV replication are researched, and it is found that stable knockout of the mov10 gene can remarkably promote replication of RABV CVS11 and SRV9. Technical support is provided for exploration of MOV10 biological functions and development and production of RABV inactivated vaccines and recombinant virus vaccines with RABV as carriers.

The invention discloses a culture method of high-activity human urine-derived stem cells, which relates to the technical field of biological medicine, and is technically characterized by comprising the following steps: collecting urine samples of pregnant and lying-in women, coating a culture plate with gelatin, inducing adherence, performing passage amplification, performing immunofluorescence identification, performing function detection and other optimized conditions, and separating and culturing the stem cells. Compared with urine-derived stem cells of normal adults, the stem cells derived from pregnant women have stronger activity, higher dryness and faster multiplication capacity. The invention provides a novel and superior cell source for tissue engineering and regenerative medicine.

The invention provides application of ginsenoside Re carbon nanodots in the field of preparation of pharmaceutical preparations for resisting kidney cancer and / or inhibiting kidney cancer A498 cells. The ginsenoside Re carbon nanodots (Re-CDs) prepared by the invention have the characteristics of uniform particle size distribution, good water solubility, low biotoxicity, high cell membrane permeability and the like, also have good time, pH value and salt stability, and particularly have a relatively high inhibition effect on kidney cancer A498 cells and kidney cancer, whether in vitro or in vivo. Through transcriptomics detection, qPCR (quantitative polymerase chain reaction) verification, immunofluorescence detection and Western blot methods, a molecular mechanism of the Re-CDs anti-A498 cell is disclosed on the cellular level. The result shows that the Re-CDs can promote the cycle arrest and apoptosis of the A498 cells through the PI3K / AKT signal channel. The invention provides a new research strategy for anti-kidney cancer treatment based on CDs nano medicine in the future.

The application discloses a hybridoma cell strain 6F92E10, a monoclonal antibody thereof and application thereof, and belongs to the technical field of biotechnology.The application provides a hybridoma cell strain secreting an anti-mucinophilic Akkermansia monoclonal antibody.The antibody secreted by the hybridoma cell strain only combines with AKKermansia and does not cross-react with other common intestinal bacteria.In addition, the application solves how to detect the adhesion and colonization of mucinophilic Akkermansia in the colon of a mouse by using the prepared monoclonal antibody through an indirect immunofluorescence localization experiment, and expands the application range of the antibody.

The application provides a cell fixing solution for a myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) and a product and application thereof, and relates to the technical field of in-vitro detection. The cell fixing solution provided by the application is composed of polyoxymethylene, formaldehyde, acetic acid, raffinose and a buffer solution, can effectively fix the cell morphology, maximally retains the natural spatial conformation and antigen epitope integrity of myasthenia gravis related antigens AChR, Titin, RyR1, MuSK and LRP4, reduces the problems of antigen denaturation, epitope shielding and protein loss in the fixing process, can efficiently and accurately realize the synchronous joint detection of various specific antibodies, and the myasthenia gravis antibody spectrum (IgG) detection kit (cellular immunofluorescence method) prepared by the application has stable detection results, and has important clinical application value and industrial popularization prospect.

The invention discloses a rapid degreasing method for a biological tissue sample, which comprises the following steps: sequentially carrying out fixing, tissue dehydration, azeotropic degreasing, tissue rehydration and other treatments on the sample, and the degreasing solution is composed of alcohols and hydrocarbons according to a mass ratio of 1: 1-1: 2. According to the rapid degreasing method provided by the invention, the lipid in the tissue is efficiently extracted through mixed azeotropy of the alcohol and hydrocarbon organic reagents, so that the tissue is transparent and transparent; the problem of poor degreasing in tissues is solved by utilizing the high permeability characteristic of the micromolecular organic reagent; the dissolving capacity to phospholipid and cholesterol is improved by mixing organic reagents; through azeotropy, the degreasing efficiency is improved, the degreasing time is shortened, the internal permeability effect of the tissue is improved, and internal and external uniform permeability of the tissue is realized; by adjusting the components of the organic reagent, boiling rapid degreasing at low temperature is realized, and the retention of a fluorescence signal is improved; the tissue treated by the method is transparent and small in deformation, a fluorescent protein signal can be maintained, and the immunofluorescence staining effect can be improved.

The present invention belongs to the technical field of in vitro cell differentiation. The present invention provides a method, composition and application for separation, identification and adipogenic differentiation of mammalian adipocytes. The mechanical method combined with collagenase digestion method is used to successfully separate and obtain mammalian adipocytes. Immunofluorescence technology is used to identify the obtained adipocytes. The adipogenic differentiation method of adipocytes is explored by a combination of multiple adipogenic induction factors. The differentiated mature adipocytes are identified by Oil Red O staining, BODIPY staining, triglyceride (TAG) content determination and / or Western blot technology. The results show that the adipogenic differentiation method of the present invention has good beneficial effects, is an ideal method for studying adipocyte differentiation, and has important application value in the fields of animal husbandry, biomedicine and biological meat cultivation.

The invention relates to the technical field of biological medicines, and discloses a blocking antibody targeting CXCL6 and an application of the blocking antibody in preparation of antitumor drugs. The antibody or antigen-binding fragment thereof is capable of binding specifically to human CXCL6 protein with high affinity (e.g., Kd < = 1 nM). According to the invention, the specificity and high affinity of the antibody are verified by Western Blot, immunofluorescence, immunohistochemistry and surface plasmon resonance (SPR) technologies. Functional experiments show that the antibody can effectively block CXCL6-induced neutrophil chemotaxis, including in Transwell, a three-dimensional gel model and a zebra fish living body model. Besides, in a mouse MC38 colon cancer model, the antibody shows remarkable anti-tumor activity and can inhibit tumor growth driven by CXCL6. The invention also provides a pharmaceutical composition containing the antibody, and application of the antibody in preparation of drugs for preventing or treating diseases (such as inflammatory diseases, autoimmune diseases and cancers) related to abnormal expression or activity of CXCL6.

The embodiment of the invention discloses application of an anti-toxoplasma gondii elongation factor monoclonal antibody in toxoplasma gondii detection and a detection method, and belongs to the technical field of toxoplasma gondii detection, a toxoplasma gondii elongation factor is EF-1alpha, and early diagnosis and discovery of toxoplasma gondii infection are crucial to control of the disease. The monoclonal antibody for resisting the toxoplasma gondii elongation factor EF-1 alpha is an antibody which has great potential to be applied to diagnosis of toxoplasmosis, the expression of the toxoplasma gondii elongation factor 1-alpha is highly conservative, and the monoclonal antibody plays an important role in pathogenesis of parasites and host cell invasion. The monoclonal antibody for resisting the EF-1alpha with the gene number of TGME49286420 is found for the first time in the invention, the expression of the monoclonal antibody in the toxoplasma gondii is very specific, and the toxoplasma gondii can be detected through a Western-blot technology and an indirect immunofluorescence technology.

The invention discloses application of ailanone in preparation of a medicine for treating feline infectious peritonitis, and belongs to the field of biological medicine. The change of the expression quantity of the feline infectious peritonitis virus N protein is detected through indirect immunofluorescence and western blot, and the change of the quantity titer of the feline infectious peritonitis virus is detected through TCID50. Results show that ailanone has an obvious effect of resisting the feline infectious peritonitis virus, the inhibitory effect on the feline infectious peritonitis virus is enhanced along with increase of the drug concentration, and the half effective concentration is 0.09 mu M. Meanwhile, drug inhibition tests show that ailanone has no inhibition effect on feline calicivirus. The invention provides a novel therapeutic drug and strategy for treating feline infectious peritonitis.

The invention provides an anti-novel duck reovirus monoclonal antibody hybridoma cell strain, a monoclonal antibody, a reagent or a kit and application, and belongs to the technical field of novel duck reovirus detection. The monoclonal antibody hybridoma cell strain capable of resisting the novel duck reovirus is named as a hybridoma cell strain NDRV Mab-Sigma C-9, and the preservation number of the hybridoma cell strain NDRV Mab-Sigma C-9 is CCTCC (China Center for Type Culture Collection) NO: C2024284. An indirect immunofluorescence kit prepared from the monoclonal antibody secreted by the monoclonal antibody hybridoma cell strain for resisting the novel duck reovirus has good specificity and sensitivity. The kit not only can be used for detecting exogenous viruses of the NDRV in poultry virus live vaccines, but also can be used for clinical detection and epidemiological investigation of the NDRV.

The application belongs to the technical field of immune detection, and particularly relates to a quantum dot labeled testosterone propionate direct competition fluorescence immune detection method. The application prepares a monoclonal antibody, and couples CdSe / ZnS (core / shell) quantum dots with the prepared anti-TP monoclonal antibody to synthesize a quantum dot (QDs) labeled anti-TP-mAb-QDs immune fluorescence probe, and construct a quantum dot labeled testosterone propionate direct competition fluorescence immune detection system for detecting testosterone propionate. The method for detecting testosterone propionate by the quantum dot labeled direct competition fluorescence immune detection method is simple in operation, and can detect the residual content of testosterone propionate in a sample to be detected without adding a chromogenic substance. The operation and reaction can be completed in one step. The method is simple, efficient, sensitive, low in detection cost, and can be applied to rapid detection of TP residues in feed, and has good accuracy.

The invention relates to the technical field of biology, in particular to an anti-CD70 monoclonal antibody, a hybridoma cell strain and application thereof. The invention provides a monoclonal antibody. Amino acid sequences of three CDR regions of a heavy chain of the monoclonal antibody respectively have amino acid sequences shown as SEQ ID NO: 11, 12 and 13; the amino acid sequences of the three CDR regions of the light chain of the gene respectively have the amino acid sequences shown as SEQ ID NO: 6, 7 and 8. The anti-CD70 monoclonal antibody provided by the invention can specifically recognize a CD70 recombinant protein expressed by eukaryotic expression and a CD70 protein expressed on a cell membrane. The CD70 detection kit constructed by the anti-CD70 monoclonal antibody is high in sensitivity and good in specificity, and has a better application effect in various detections including enzyme-linked immunosorbent assay, flow cytometry, immunofluorescence and the like.

The present invention discloses a method for cell immunofluorescence operation under a 2D rotating cell simulated weightlessness model, comprising the following steps: Fix a small round piece with a diameter of 14 mm on a square glass slide using a dental orthodontic rubber band. After autoclaving, inoculate cells onto the square glass slide according to the original method, place it on the rotating chamber fixing rack, and conduct a rotating simulated weightlessness experiment; after rotation is completed, take out the square glass slide, remove the small round piece and conduct a cell immunofluorescence experiment. When incubating the primary antibody, stick a plastic wrap on the back of the lid of a 24-well plate, then drop 30 μL of the primary antibody on the lid, and invert the side of the small round piece with cells onto the droplet; the same method is used for secondary antibody incubation. The present invention can minimize the usage amount of the primary antibody and the secondary antibody during immunofluorescence without affecting the immunofluorescence effect and without the need for an immunohistochemical pen, and the samples can be fully utilized.

The invention belongs to the technical field of biology, and particularly relates to a recombinant monoclonal antibody of sheep anti-bluetongue virus VP7 protein. A sheep anti-bluetongue virus antibody library is obtained through a single cell V (D) J sequencing technology, a sheep anti-bluetongue virus VP7 protein recombinant monoclonal antibody is screened and successfully expressed, and it is identified through indirect ELISA and cellular immunofluorescence experiments that the recombinant monoclonal antibody has high affinity with bluetongue virus and can be specifically combined with VP7 protein. The recombinant monoclonal antibody is used as a competitive antibody to establish a competitive ELISA detection method aiming at the bluetongue virus VP7 protein, high specificity of bluetongue antibody detection can be realized, and a basis is provided for mastering the epidemiology of bluetongue virus and evaluating the immune effect of vaccines.

This invention belongs to the field of biodetection technology, specifically relating to a material for detecting anti-Caspr1 antibodies and its preparation method. The invention constructs an expression plasmid capable of highly expressing the Caspr1 antigen, transfects it into HEK293T cells, and modifies the original antigen sequence during construction to achieve normal membrane expression. Subsequently, a modified cell culture protocol is used to obtain a material for detecting anti-Caspr1 antibodies based on cellular immunofluorescence assay. This invention, based on cellular immunofluorescence, avoids the limitations of flow cytometry, which is complex and requires expensive equipment. By modifying the protein expression mode to normal membrane expression, it avoids cell permeabilization, avoids false negatives caused by antigen conformational changes in enzyme-linked immunosorbent assay (ELISA) and Western blotting, and avoids false negatives caused by transmembrane expression due to transfection with the original Caspr1 sequence.

This invention belongs to the field of biodetection technology, specifically relating to a material for detecting anti-NF155 antibodies and its preparation method. This invention constructs an expression plasmid capable of highly expressing the NF155 antigen, transfects it into HEK293T cells, and modifies the pCDH vector with enhancers during construction. Subsequently, a modified cell culture protocol is used to obtain a material for detecting anti-NF155 antibodies based on a cell immunofluorescence methodology. This invention uses a cell immunofluorescence methodology to maximize the preservation of the antigen's spatial conformation through cell expression and antigen immobilization, preventing false negatives due to changes in binding sites. This invention selects the lentiviral vector pCDH to avoid the problem of non-specific binding that is difficult to distinguish, as the proteins expressed by common target gene vectors such as pcDNA3.1 may themselves contain antibody binding sites. This improves detection specificity and solves the problem of false negatives.

The invention relates to the technical field of antibodies, and particularly provides an anti-human TTC22v1 monoclonal antibody, a hybridoma cell strain prepared from the anti-human TTC22v1 monoclonal antibody and application of the anti-human TTC22v1 monoclonal antibody. The monoclonal antibody can specifically recognize the 432 -569 amino acid region of the TTC22v1 protein, and is secreted by a hybridoma cell strain TTC22v1-06 # with the preservation number of CCTCC (China Center For Type Culture Collection) NO: C202594. The antibody has high specificity and high sensitivity, can obviously distinguish TTC22v1 and TTC22v2 proteins, is especially suitable for Western blot and cell immunofluorescence detection, can effectively detect expression of endogenous TTC22v1 proteins in colon cancer cells, provides a reliable detection tool for research of TTC22v1 in tumor research and disease diagnosis, and has a wide application prospect.

The invention relates to the technical field of immunofluorescence detection reagents, in particular to a chemiluminescence reaction system of cerium dioxide-based alkaline phosphatase, a chemiluminescence immunodetection kit and application of the chemiluminescence reaction system and the chemiluminescence immunodetection kit. The chemical reaction system comprises coated magnetic beads and a growth differentiation factor 15 antibody containing a ceria-based alkaline phosphatase label, and the surface of each coated magnetic bead is coated with an anti-growth differentiation factor 15 antibody and streptavidin; wherein the weight m1 of the coated magnetic beads and the weight m2 of the antibody marked with the ceria-based alkaline phosphatase and used for marking the growth differentiation factor 15 meet the relational expression that m1: m2 is smaller than or equal to 400: 1. According to the chemiluminescence reaction system, ceria-based alkaline phosphatase is used for replacing traditional alkaline phosphatase, and the stability and accuracy of chemiluminescence immunodetection of the growth differentiation factor 15 can be synchronously improved.

The invention provides an anti-medetomidine monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. Medetomidine is used for immunizing a Balb / c mouse, splenocytes of the mouse are fused with myeloma cells, hybridoma cells with high specificity are obtained through specific high-throughput screening, a large amount of mouse ascites is obtained through culture and re-immunization, and the mouse ascites with high specificity is obtained. And the medetomidine monoclonal antibody with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting medetomidine. The anti-medetomidine monoclonal antibody disclosed by the invention can be used for immunological detection such as immunoblotting and immunofluorescence, and the obtained antibody is proved to have good specific binding capacity.

This application relates to the field of biomedical technologies, and specifically discloses a transcription factor HOMEZ phosphorylation site-specific antibody, its preparation method and applications. The specific antibody provided in this application can specifically recognize the phosphorylation of threonine at position 451 of HOMEZ in tumor specimens, thereby judging the prognosis of tumors and providing potential therapeutic targets for the diagnosis and treatment of clinical tumors. Moreover, the specific antibody of this application can be used in Western blot experiments to detect the expression differences between normal cells and tumor cells, which helps to study the role of phosphorylation modification of HOMEZ protein in the occurrence and development of tumor diseases. It can also be used in experiments such as immunofluorescence and immunohistochemical staining to detect the phosphorylation level of HOMEZ protein in clinical specimens, and has broad clinical application prospects in aspects such as disease diagnosis, treatment and prognosis determination.

The invention belongs to the technical field of biological medicines, and particularly relates to a human NSUN2 protein 190th lysine site lactic acid antigen, an antibody, a preparation method and application thereof. Relates to the technical field of lactylated antibody preparation, and the preparation method comprises the following steps: S01, carrying out lactylation on 190th lysine in a polypeptide of an amino acid sequence, and coupling with a carrier protein to obtain an initial antigen, the carrier protein comprising hemocyanin KLH; s02, injecting the obtained antigen into a living body culture sample for immune culture, and collecting whole blood after a preset period to obtain multi-antibody serum; and S03, purifying to obtain an iterative antibody. According to the invention, the expression difference in sensitive and drug-resistant tumor cells and tumor tissues can be detected by directly applying Western Blotting, immunofluorescence and immunohistochemistry, so that a powerful guarantee is provided for the detection of tumor sensitivity.

The present invention discloses a monoclonal antibody for recognizing human liver progenitor cells and a hybridoma cell line HLPC1. Human liver progenitor cells are used as antigens and a hybridoma cell line HLPC1 is constructed by using monoclonal antibody technology, and the deposit number is CCTCC NO: C202253. The hybridoma cell line HLPC1 secretes a monoclonal antibody for recognizing human liver progenitor cells. Flow cytometry, immunohistochemistry, immunofluorescence and immunoblotting are established with this monoclonal antibody as a probe for detecting and analyzing human liver progenitor cells. The present invention provides a specific method for the study of human liver progenitor cells, and various detection techniques based on monoclonal antibodies of human liver progenitor cells can also be used in the study of human liver damage and regeneration.

The present invention provides a kind of kit and its use for detecting psychotropic drugs in hair, the kit includes hair cleanser and hair digester, the hair cleanser includes Tween-20 and TXR-1, and the hair digester includes dithiothreitol, tris (2-carboxyethyl) phosphine hydrochloride and CHAPS. The hair sample is pre-treated with the kit provided by the present invention, and the pollutants attached to the hair sample can be effectively removed, the operating steps are simplified, the accuracy and stability of the test results are improved, and the sample extract can still be accurately detected after being stored for a certain period of time. In addition, the psychotropic drugs in the sample extract are detected in combination with quantum dot immunofluorescence chromatography, and a variety of new psychotropic drugs can be fully extracted and accurately detected, which greatly improves the sensitivity and specificity of the detection method, and is conducive to rapid screening on site.

The invention discloses a monoclonal antibody for identifying porcine liver mesenchymal stem cells and a hybridoma cell strain PLM1. The swine liver mesenchymal stem cells are used as antigens, a hybridoma cell strain PLM1 with the preservation number of CCTCC NO: C2022300 is constructed by using a monoclonal antibody technology, the hybridoma cell strain PLM1 secretes a monoclonal antibody for identifying the swine liver mesenchymal stem cells, and the monoclonal antibody is used as a probe to be applied to flow cytometry, immunohistochemistry, immunofluorescence, immunoblotting and the like. The kit is used for detecting and analyzing the swine liver mesenchymal stem cells. The invention provides a specific method for researching the porcine liver mesenchymal stem cells, and various detection technologies of the monoclonal antibody based on the porcine liver mesenchymal stem cells can also be applied to research on porcine liver injury and regeneration.

The embodiment of the invention discloses application of an anti-toxoplasma gondii pulmonary alveolar protein structural domain monoclonal antibody containing intermediate silk IMC1 in toxoplasma gondii detection and a detection method, and belongs to the technical field of toxoplasma gondii detection. Early diagnosis and discovery of toxoplasma gondii infection are crucial to control of the disease, the monoclonal antibody for resisting the toxoplasma gondii and containing the intermediate silk IMC1 alveolar protein structural domain is a very potential antibody applied to diagnosis of toxoplasmosis, and the toxoplasma gondii and containing the intermediate silk IMC1 alveolar protein structural domain is crucial to the structural integrity of tachyzoite. An important role is played in pathogenesis and host cell invasion of the parasites; the monoclonal antibody resisting the pulmonary alveolar protein structural domain with the gene number of TGVEG231640 and containing the intermediate silk IMC1 is found for the first time in the invention, the expression of the monoclonal antibody in the toxoplasma gondii is very specific, and the toxoplasma gondii can be detected through a Western-blot technology and an indirect immunofluorescence technology.

The invention belongs to the technical field of veterinary biology, and particularly relates to a preparation method and application of an African swine fever virus I73R protein monoclonal antibody. The main technology comprises the following steps: immunizing a BALB / c mouse by using a recombinant I73R protein prepared by prokaryotic expression as an antigen, and carrying out cell fusion, indirect ELISA method screening, limited dilution method subcloning and hybridoma continuous subculture by using a hybridoma technology to obtain a hybridoma cell line capable of stably secreting an anti-African swine fever virus I73R protein monoclonal antibody. The invention also discloses a sequence of an immunogen of the prepared monoclonal antibody, a subtype of the monoclonal antibody, a CDR sequence, an epitope recognized by the monoclonal antibody, a preservation number of a hybridoma cell strain and application of the monoclonal antibody in a Western Blot experiment, an indirect immunofluorescence experiment, an immunoprecipitation experiment, an immunofluorescence experiment, a cytotoxic experiment and a cytotoxic experiment. The invention also relates to a neutralization experiment and an application in a blocking ELISA method for detecting the African swine fever virus antibody in swine serum.